SVF
Level D· Preclinical EvidenceAnimal Study

Angiopep-2-engineered extracellular vesicles derived from spinal cord injury-responsive brown adipose tissue for targeted neuroinflammation modulation.

Xiang S., Qin T., Qin Y., Sun Y., Zhou M., Tang Y.

Animal Study on Spinal Cord Injury, Neuroinflammation, Chronic Inflammation, published in J Nanobiotechnology (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Nanobiotechnology (2026)
Country
England
Reported sample size
—
PMID
41787360
DOI
10.1186/s12951-026-04163-1

Abstract (original English)

Spinal cord injury (SCI) affects over 15 million people globally with no curative treatments available. While primary mechanical trauma initiates tissue damage, secondary pathological cascades including neuroinflammation and mitochondrial dysfunction expand the injury. Current clinical interventions focus only on symptom management without restoring neural function. This study investigates the role of brown adipose tissue (BAT) in SCI repair through extracellular vesicles (EVs). Using 18 F-FDG PET/CT imaging, this study discovered significant BAT activation post-SCI, peaking at 7 days, which was confirmed by histological analysis. Activated BAT increased EV secretion, with secreted EVs being selectively taken up by spinal microglia. miRNA sequencing identified miR-692 as the key EV cargo that silenced pro-inflammatory Spp1 gene in microglia, promoting their anti-inflammatory polarization and enhancing neuronal survival. Further development of a targeted delivery system using Angiopep2-modified BAT-EVs encapsulated in GelMA hydrogel for sustained release at injury sites significantly reduced lesion volume and improved functional recovery. The research establishes the BAT-EV-microglia axis as crucial for SCI repair and presents a promising biomaterial-enhanced EV therapy for SCI treatment, marking a significant advancement in regenerative medicine.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
AnimalsSpinal Cord InjuriesAdipose Tissue, BrownExtracellular VesiclesMicroRNAsMicrogliaPositron Emission Tomography Computed TomographyFemaleNeuroinflammatory DiseasesMice
Back & SpineSpinal Cord InjuryNeuroinflammationChronic Inflammation
View on PubMedDOI

Related research